share_log

Canopy Growth | 8-K: Canopy Growth Reports Second Quarter Fiscal Year 2025 Financial Results

Canopy Growth | 8-K: Canopy Growth Reports Second Quarter Fiscal Year 2025 Financial Results

Canopy Growth | 8-K:Canopy Growth公佈2025財年第二季度財務業績
美股SEC公告 ·  11/08 20:15

牛牛AI助理已提取核心訊息

On November 8, 2024, Canopy Growth Corporation, a leading cannabis company, reported its financial results for the second quarter of fiscal year 2025, which ended on September 30, 2024. The company announced a decrease in net revenue by 9% compared to the same quarter of the previous year, attributing the decline to divested businesses. However, excluding these divested businesses, net revenue saw a 3% increase. Canopy Growth's gross margin improved by 100 basis points to 35%, primarily due to cost savings and a shift towards higher-margin medical cannabis sales. The company's operating loss widened from $7 million in Q2 FY2024 to $46 million in Q2 FY2025, largely because the previous year's results benefited from the sale of a facility. Adjusted EBITDA loss improved by 54% year-over-year, and free cash flow...Show More
On November 8, 2024, Canopy Growth Corporation, a leading cannabis company, reported its financial results for the second quarter of fiscal year 2025, which ended on September 30, 2024. The company announced a decrease in net revenue by 9% compared to the same quarter of the previous year, attributing the decline to divested businesses. However, excluding these divested businesses, net revenue saw a 3% increase. Canopy Growth's gross margin improved by 100 basis points to 35%, primarily due to cost savings and a shift towards higher-margin medical cannabis sales. The company's operating loss widened from $7 million in Q2 FY2024 to $46 million in Q2 FY2025, largely because the previous year's results benefited from the sale of a facility. Adjusted EBITDA loss improved by 54% year-over-year, and free cash flow saw a 16% improvement. Canopy Growth's balance sheet was strengthened with a cash and short-term investments balance of $231 million as of September 30, 2024. The company's medical cannabis business in Canada and international markets showed growth, with net revenue increasing by 16% and 12%, respectively. Storz & Bickel, a subsidiary known for vaporizer technology, saw a 32% increase in net revenue. Canopy USA completed the acquisition of Wana Brands and is on track to close the acquisition of Acreage Holdings in the first half of 2025.
2024年11月8日,領先的大麻股公司Canopy Growth Corporation報告了截至2024年9月30日的2025財年第二季度的財務業績。該公司宣佈,與去年同期相比,淨收入下降了9%,歸因於出售的業務。但是,排除這些出售的業務後,淨收入增加了3%。Canopy Growth的毛利率提高了100個點子,達到35%,主要是由於成本節約和向更高毛利率的醫療大麻銷售方式轉變。該公司的營運虧損從2024財年第二季度的700萬美元擴大到2025財年第二季度的4600萬美元,主要是因爲前一年的業績受益於一項設施的出售。調整後的EBITDA虧損同比減少了54%,自由現金流改善了16%。截至202...展開全部
2024年11月8日,領先的大麻股公司Canopy Growth Corporation報告了截至2024年9月30日的2025財年第二季度的財務業績。該公司宣佈,與去年同期相比,淨收入下降了9%,歸因於出售的業務。但是,排除這些出售的業務後,淨收入增加了3%。Canopy Growth的毛利率提高了100個點子,達到35%,主要是由於成本節約和向更高毛利率的醫療大麻銷售方式轉變。該公司的營運虧損從2024財年第二季度的700萬美元擴大到2025財年第二季度的4600萬美元,主要是因爲前一年的業績受益於一項設施的出售。調整後的EBITDA虧損同比減少了54%,自由現金流改善了16%。截至2024年9月30日,Canopy Growth的資產負債表得到加強,現金和短期投資餘額爲23100萬美元。該公司在加拿大和國際市場的醫療大麻業務表現出增長,淨收入分別增長了16%和12%。以蒸發器技術聞名的子公司Storz & Bickel,淨收入增長了32%。Canopy USA已完成對Wana Brands的收購,並計劃在2025年上半年完成對Acreage Holdings的收購。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。